Navigation Links
New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Date:11/10/2007

Data Also Showed That Over a 6 Month Period, Nasacort AQ Did Not Cause

Significant Adrenal Suppression in This Same Age Group

BRIDGEWATER, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Data presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting suggests that the intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray may be used safely and effectively to treat children aged 2-5 years old with year-round allergic rhinitis. The same study also showed that during the study, Nasacort AQ did not show a significant effect on adrenal function among a subset of the same patients.

Caused by an allergic reaction to allergens such as house dust, animal dander, or pollen, allergic rhinitis is the most common chronic childhood disease, effecting as many as 40% of all children in the U.S.

A clinical study suggests that Nasacort AQ may present a safe and effective treatment option in children aged 2-5 years with year-round allergic rhinitis

In a multicenter, randomized, double-blind study, Nasacort AQ, given as 1 spray per nostril once daily for 4 weeks, improved combined symptoms of sneezing, nasal itching, discharge, and congestion, compared with placebo in children aged 2-5 years who have had year-round allergic rhinitis for at least one year. Nasacort AQ also showed comparable safety to placebo.

"This study suggests that Nasacort AQ may be used safely and effectively to treat young children who suffer from year-round allergies," said lead investigator Dr. Steven Weinstein of University of California at Irvine College of Medicine.

This study is the first and only randomized, double-blind, placebo-controlled study designed specifically to investigate both the efficacy and safety of an intranasal corticosteroid in this very young age group. A total of 474 patients were randomized to receive either Nasacort AQ or placebo as 1 spray per nostril once daily for 4 weeks. To particip
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. Success of Shape Up Somerville childhood obesity intervention to be presented
5. Survival data presented from phase II study of hormone-resistant prostate cancer patients
6. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
7. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
8. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
9. Horizons AMI trial data to be presented at TCT 2007
10. AMIHOT II trial data presented at TCT
11. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, ... help predict survival and the course of the disease in ... disease, Italian researchers report. , , The components in the ... progressing are called albumin and creatinine. These components are normally ... U.S. National Library of Medicine. But now it appears ...
(Date:7/22/2014)... a five-year, $3 million grant to study how ... maltreatment during childhood leave molecular marks in DNA ... The Center for Biomarker Research and Personalized Medicine ... with Duke University School of Medicine, will conduct ... National Institutes of Health, National Institute of Mental ...
(Date:7/22/2014)... radio-frequency identification (RFID) tags to hundreds of individual honey bees ... discoveries: Some foraging bees are much busier than others; and ... , The findings are reported in the journal ... about 20 percent of the foraging bees in a hive ... gathered to feed the hive. , "We found that some ...
(Date:7/22/2014)... Diego, CA (PRWEB) July 22, 2014 Today, ... geared toward teens ages 13 – 18 to help increase ... by specially trained therapists, teens will learn how to make ... “Adolescence is a time of excitement and adventure, but also ... Perper, Ph.D. and founder of Therapy Changes . , ...
(Date:7/22/2014)... Thought Technology's new Stress Control ... to help clinicians do biofeedback therapy with clients, even ... The tools in the suite assess a client's physiological ... to teach them to recuperate from stress using biofeedback. ... with stress and its negative impact on our health. ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:Radio frequency ID tags on honey bees reveal hive dynamics 2Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3
... Society Celebrates 40 Years of Specialized ... in the U.S. and Abroad April 13-19, MT LAUREL, N.J., ... of the United States, the world and Enterostomal,Therapy (ET) Nursing. The ... the beginning of the end of the,Vietnam War influenced world events. ...
... reduce body,s release of stress hormones , , MONDAY, April ... the release of stress hormones that can weaken your ... , The researchers, who previously had found that ... that mirth may be a key to better physical ...
... Nurses Association Intervention Tool Kit Reduces Patient ... Injuries/Repeat Visits and Risky Drinking, ... 10,National Alcohol Screening Day, 360 nurses in emergency departments,nationwide ... and intervention tool kit designed to address alcohol use,problems ...
... In celebration of ELLE,s 3rd,annual May green ... and spa bus that,s green inside and out ... 15, 2008 - Sunday, May 4, 2008,making one-day ... The general public will enjoy complimentary styling, mini-makeovers,beauty ...
... trials indicate that estrogen replacement therapy (ERT) may increase the ... examined whether adverse effects of ERT are related to the ... of ERT increased problems in the kidney and heart. These ... in a womans overall health. , The study, Dose-Response ...
... April 7, 2008 Penn Foster Career School,now ... skills,for working professionals. The program offerings include a ... Anatomy and Physiology, This broad overview of ... in,the health professions. Prospective nurses, medical transcriptionists, and,first ...
Cached Medicine News:Health News:WOCN: Around the World in 40 Years 2Health News:WOCN: Around the World in 40 Years 3Health News:WOCN: Around the World in 40 Years 4Health News:Heard the One About How to Beat Tension? 2Health News:Emergency Departments Nationwide Institute New Alcohol Screening and Intervention Process 2Health News:ELLE Eco-Salon & Spa Rolls Thru Southern California Offering Styling, Mini- Makeovers and Beauty Treatments 2Health News:New study finds adverse effects of estrogen replacement therapy are related to the dose 2Health News:New study finds adverse effects of estrogen replacement therapy are related to the dose 3Health News:Penn Foster Career School Offers Certificate Programs 2
(Date:7/22/2014)... ,  July 22, 2014 ... of Thomson Reuters , the world,s leading ... professionals, today announced Cortellis Clinical Trials ... marked an industry-first milestone with the documentation ... providing pharmaceutical professionals with greater and quicker ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
(Date:7/22/2014)... 22, 2014 The steady decline of ... to previously rep-friendly specialties, according to the spring ... consulting firm ZS Associates.      AccessMonitor™ ... pharmaceutical sales teams. The report examines how often ... the pharmaceutical sales reps who visit their offices. ...
Breaking Medicine Technology:Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5
... Findings from an international,multicenter, randomized, double-blind, placebo-controlled Phase ... of moderate to severe,plaque psoriasis will be presented ... the World Congress of Dermatology, which takes place ... Aires, Argentina. The presentation, entitled CNTO 1275 ...
... Study Will Assess Drug,s Benefit, Alone and With Lipitor(R), ... Cholesterol and Triglycerides -, HAYWARD, Calif., Sept. 25 ... and development of novel,therapeutics for diabetes and related metabolic ... 2 trial of MBX-8025 in overweight or,obese patients with ...
Cached Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: